Abstract:Gprc5a is a novel target gene of parathyroid hormone (PTH) signaling in osteoblastic cells. Gprc5a expression is induced by PTH via the cAMP pathway. Gprc5a negatively regulates osteoblast proliferation and differentiation. Gprc5a suppresses BMP signaling by interacting with a type I BMP receptor. Teriparatide is a peptide derived from a parathyroid hormone (PTH) and an osteoporosis therapeutic drug with potent bone formation‐promoting activity. To identify novel druggable genes that act downstream of PTH signaling and are potentially involved in bone formation, we screened PTH target genes in mouse osteoblast‐like MC3T3‐E1 cells. Here we show that Gprc5a, encoding an orphan G protein‐coupled receptor, is a novel PTH‐inducible gene and negatively regulates osteoblast proliferation and differentiation. PTH treatment induced Gprc5a expression in MC3T3‐E1 cells, rat osteosarcoma ROS17/2.8 cells, and mouse femurs. Induction of Gprc5a expression by PTH occurred in the absence of protein synthesis and was mediated primarily via the cAMP pathway, suggesting that Gprc5a is a direct target of PTH signaling. Interestingly, Gprc5a expression was induced additively by co‐treatment with PTH and 1α, 25‐dihydroxyvitamin D3 (calcitriol), or retinoic acid in MC3T3‐E1 cells. Reporter analysis of a 1 kb fragment of human GPRC5A promoter revealed that the promoter fragment showed responsiveness to PTH via the cAMP response element, suggesting that GPRC5A is also a PTH‐inducible gene in humans. Gprc5a knockdown promoted cell viability and proliferation, as demonstrated by MTT and BrdU assays. Gprc5a knockdown also promoted osteoblast differentiation, as indicated by gene expression analysis and mineralization assay. Mechanistic studies showed that Gprc5a interacted with BMPR1A and suppressed BMP signaling induced by BMP‐2 and constitutively active BMP receptors, ALK2 (ACVR1) Q207D and ALK3 (BMPR1A) Q233D. Thus, our results suggest that Gprc5a is a novel gene induced by PTH that acts in an inhibitory manner on both cell proliferation and osteoblast differentiation and is a candidate for drug targets for osteoporosis.

Activation of TGR5 Promotes Osteoblastic Cell Differentiation and Mineralization.

LGR5 enhances the osteoblastic differentiation of MC3T3-E1 cells through the Wnt/β-catenin pathway

Activation of GPR30 promotes osteogenic differentiation of MC3T3-E1 cells: An implication in osteoporosis

Matrix Gla Protein Promotes the Bone Formation by Up-Regulating Wnt/β-Catenin Signaling Pathway.

LGR6 Promotes Osteogenesis by Activating the Wnt/beta-catenin Signaling Pathway

GPR35 regulates osteogenesis via the Wnt/GSK3/-catenin signaling pathway

Oleanolic Acid Promotes Skeletal Muscle Fiber Type Transformation by Activating TGR5-mediated CaN Signaling Pathway.

TGR5, Not Only a Metabolic Regulator

LGR6 promotes osteogenesis by activating the Wnt/β-catenin signaling pathway

Γ-Aminobutyric Acid Promotes Osteogenic Differentiation of Mesenchymal Stem Cells by Inducing TNFAIP3.

Gprc5a is a novel parathyroid hormone‐inducible gene and negatively regulates osteoblast proliferation and differentiation

TGR5 Activation Promotes Stimulus-Secretion Coupling of Pancreatic β-Cells via a PKA-Dependent Pathway

Osteogenesis Is Improved by Low Tumor Necrosis Factor Alpha Concentration through the Modulation of Gs-Coupled Receptor Signals

AMPK Promotes Osteogenesis and Inhibits Adipogenesis Through AMPK-Gfi1-OPN Axis.

Loss of MGAT5 is Involved in the Impaired Osteogenic Differentiation of Bone Marrow Mesenchymal Stem Cells

Tetrahydroxystilbene Glucoside Regulates Proliferation, Differentiation, and OPG/RANKL/M-CSF Expression in MC3T3-E1 Cells via the PI3K/Akt Pathway

Effect of ANGPTL7 on Proliferation and Differentiation of MC3T3-E1 Cells

Dual Targeting of Bile Acid Receptor‐1 (TGR5) and Farnesoid X Receptor (FXR) Prevents Estrogen‐Dependent Bone Loss in Mice

Long Noncoding RNA <i>GAS5</i> Inhibits Osteogenic Differentiation through MicroRNA 382-3p/<i>TAF1</i> Signaling

Gamma-Tocotrienol Stimulates the Proliferation, Differentiation, and Mineralization in Osteoblastic MC3T3-E1 Cells

Update on the development of TGR5 agonists for human diseases